Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Hematologic Malignancies

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1534158

Prognostic Impact of Initial Platelet Count and Post-Induction Platelet Recovery in Elderly AML Patients: Associated with Circulating cytokines

Provisionally accepted
Chun Ling Chun Ling 1,2*Neng-Neng Cao Neng-Neng Cao 2Xiao-Wei Niu Xiao-Wei Niu 3Shi-Yun Xu Shi-Yun Xu 1Wen-Yu Gong Wen-Yu Gong 1Wen-Qiang Bao Wen-Qiang Bao 1Qi-Chuan Jin Qi-Chuan Jin 1Yin Wang Yin Wang 1Jing Wu Jing Wu 1Chang-Zhi Zhao Chang-Zhi Zhao 1Wen-Jing Fu Wen-Jing Fu 1Qi-Guo Zhang Qi-Guo Zhang 1Shan-Shan Feng Shan-Shan Feng 1Dao-Yuan Li Dao-Yuan Li 1
  • 1 First People’s Hospital of Chuzhou, Chuzhou, China
  • 2 Second Hospital of Anhui Medical University, Hefei, Anhui Province, China
  • 3 First Hospital of Lanzhou University, Lanzhou, Gansu Province, China

The final, formatted version of the article will be published soon.

    AbstractObjective: Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with various clinical features influencing its prognosis. The aim of this study to evaluate the impact of platelet count at diagnosis and platelet recovery after induction chemotherapy on the survival outcomes of elderly AML patients.Methods: A total of 109 elderly patients with AML who were treated in our center between 2017 and 2023 were evaluated. According to the median platelet counts at the time of new diagnosis, the cases were divided into a low platelet counts group (≤40×109/L, n=54) and a high platelet count group (>40×109/L, n=55). Platelet recovery times were accepted as the periods from the beginning of induction chemotherapy to a platelet count of ≥20×109/L 3 days in a row, respectively. The median time to platelet recovery was 25 days (range12-47) for all patients. Therefore, platelet recovery in the first 25 days was defined as early platelet recovery and at >25 days it was defined as late platelet recovery.Results: Low platelet counts at diagnosis and early recovery of platelet counts after induction therapy indicate longer overall survival (OS) and Leukemia-free survival (LFS). Patients with high platelet counts at diagnosis and those with delayed platelet recovery after induction therapy exhibited elevated levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). Additionally, patients with high platelet counts at diagnosis also had relatively higher levels of interleukin-8 (IL-8).Conclusion: Platelets can be used as a prognostic biomarker for elderly AML and may be associated with circulating cytokines.

    Keywords: Acute Myeloid Leukemia, platelets, Circulating cytokines, prognostic, geriatric

    Received: 25 Nov 2024; Accepted: 10 Feb 2025.

    Copyright: © 2025 Ling, Cao, Niu, Xu, Gong, Bao, Jin, Wang, Wu, Zhao, Fu, Zhang, Feng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chun Ling, First People’s Hospital of Chuzhou, Chuzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more